Buprenorphine vs Buprenorphine/Naloxone on the Effects of Maternal Symptomatology

• Status: Withdrawn
• Trial end date: 2020-03-22
• Target enrollment: 0
• Participant gender: Female

Summary

This study will assesses the efficacy of buprenorphine/naloxone vs buprenorphine on maternal withdrawal symptoms and drug cravings.

This is a randomized controlled trial to a cohort of pregnant women seeking medication-assisted treatment for opioid use disorders. Half of participants will receive buprenorphine, while the other half of participants receive a combination of buprenorphine/naloxone

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Stony Brook University
• Treatments: Buprenorphine; Buprenorphine, Naloxone Drug Combination; Naloxone

Criteria

Inclusion Criteria:

• 18 years of age and older

• With a confirmed viable intrauterine pregnancy

• Opioid Use Disorder

• Care in a Stony Brook Medicine OBGYN clinical office sites

• Medication-assisted treatment through Stony Brook Medicine OBGYN office sites

Exclusion Criteria:

• Known or suspected allergy to buprenorphine or buprenorphine/naloxone

• Carrying a fetus with known aneuploidy or anomaly